bioAffinity Technologies announced it has been granted a patent in Hong Kong for its proprietary platform technology used in lung cancer detection. This patent strengthens the company's intellectual property in a key Asian market, potentially facilitating future commercialization efforts in a region with a high incidence of lung cancer.
bioAffinity Technologies announced the Hong Kong Intellectual Property Department granted a patent for its lung cancer detection technology. This is significant because it provides dual patent protection in both Hong Kong and China, which are crucial markets given Asia accounts for nearly two-thirds of global lung cancer cases. For BIAF, this strengthens its intellectual property portfolio and positions its CyPath Lung product for potential entry into the lucrative Asian market, offering a long-term growth opportunity. While not an immediate revenue driver, it de-risks future commercialization efforts and could attract partnerships or investments. The short-term impact might be modest, but it's a positive step for the company's strategic expansion.